FDA Approves Cardamyst Spray for PSVT

By PPN StaffThe FDA approved etripamil (Cardamyst, Milestone Pharmaceuticals) nasal spray for episodes of paroxysmal supraventricular tachycardia (PSVT) in adults.During PSVT episodes, a person’s heart rate can reach well over 100 beats per minute, causing symptoms such as heart palpitations, lightheadedness, and fainting. In rare cases, PSVT can lead to dilated cardiomyopathy.Etripamil is a rapid-acting calcium channel blocker. The approval was based on data from the phase 3 RAPID trial (